Abstract
Vascular calcification, both in the coronary and in the peripheral arteries, is associated with increased cardiovascular (CV) risk. However, agents that prevent vascular calcification (e.g. estrogens or calcimimetic agents) might have neutral or detrimental effects on CV events. Moreover, statins and antihypertensive agents do not appear to modify vascular calcification, despite their established benefits on CV disease prevention. On the other hand, recent data suggest that microRNAs play a role in the regulation of vascular calcification. It is therefore possible that modulation of the expression of microRNAs might represent a useful strategy for preventing or delaying the progression of this process.
Keywords: Vascular calcification, cardiovascular risk, microRNA, statins, coronary artery calcium, aortic stenosis.
Current Vascular Pharmacology
Title:Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs
Volume: 14 Issue: 2
Author(s): Konstantinos Tziomalos, Vasilios G. Athyros and Asterios Karagiannis
Affiliation:
Keywords: Vascular calcification, cardiovascular risk, microRNA, statins, coronary artery calcium, aortic stenosis.
Abstract: Vascular calcification, both in the coronary and in the peripheral arteries, is associated with increased cardiovascular (CV) risk. However, agents that prevent vascular calcification (e.g. estrogens or calcimimetic agents) might have neutral or detrimental effects on CV events. Moreover, statins and antihypertensive agents do not appear to modify vascular calcification, despite their established benefits on CV disease prevention. On the other hand, recent data suggest that microRNAs play a role in the regulation of vascular calcification. It is therefore possible that modulation of the expression of microRNAs might represent a useful strategy for preventing or delaying the progression of this process.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Athyros G. Vasilios and Karagiannis Asterios, Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/157016111402160208150816
DOI https://dx.doi.org/10.2174/157016111402160208150816 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Critical Approach of Guideline Therapeutic Recommendations for NAFLD
Current Vascular Pharmacology Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism
Current Pharmaceutical Design Application of Dual-Source CT Coronary Angiography in Type 2 Diabetic Patients with Symptomatic Coronary Heart Disease
Current Vascular Pharmacology Patents and Heart Valve Surgery - I: Mechanical Valves
Recent Patents on Cardiovascular Drug Discovery Endothelial Dysfunction in Hyperglycemia as a Trigger of Atherosclerosis
Current Diabetes Reviews Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Dendrimers: General Aspects, Applications and Structural Exploitations as Prodrug/Drug-delivery Vehicles in Current Medicine
Mini-Reviews in Medicinal Chemistry Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry Rheumatic Heart Disease: Pathogenesis and Vaccine
Current Protein & Peptide Science An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Monocytes and Macrophages as Cellular Targets in Liver Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation
Current Cardiology Reviews Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Effects of Elicitors, Viticultural Factors, and Enological Practices on Resveratrol and Stilbenes in Grapevine and Wine
Mini-Reviews in Medicinal Chemistry Matricellular Proteins in Myocardial Infarction
Current Cardiology Reviews